Treatment-resistant Hypertension Market Size in the 7MM was USD 13 billion in 2021

March 21 03:10 2023
Treatment-resistant Hypertension Market Size in the 7MM was USD 13 billion in 2021

DelveInsight’s analysts estimate that the Treatment-resistant Hypertension market is expected to show positive growth, mainly attributed to increased prevalence and the anticipated launch of novel therapies by the key companies such as Idorsia Ltd, Janssen Biotech, Quantum Genomics SA, CinCor Pharmaduring, and others the forecast period (2019–2032).


The Treatment-resistant Hypertension market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted Treatment-resistant Hypertension symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Treatment-resistant Hypertension symptoms, treatment practice/algorithm, and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.


Key takeaways from the Treatment Resistant Hypertension Market Research Report


  • As per DelveInsight analysis, the Treatment-resistant Hypertension market size was over USD 13.4 billion in 2021, which is further expected to increase by 2032.


  • As per the estimates, the total Treatment-resistant Hypertension prevalent population in the 7MM was more than 16 million in 2021.


  • Key Treatment-resistant Hypertension companies such as Idorsia Ltd, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences, and others


  • The Treatment-resistant Hypertension pipeline therapies include Aprocitentan, Firibastat (QGC001), CIN-107, IONIS-AGT-LRx, and others.


Discover more about therapies set to grab major Treatment-resistant Hypertension market share @ Treatment-resistant Hypertension Market Size


Treatment Resistant Hypertension Overview

Treatment-resistant Hypertension (RHTN) is defined as uncontrolled blood pressure despite the use of ≥3 antihypertensive agents of different classes, including a diuretic, usually thiazide-like, a long-acting calcium channel blocker, or a blocker of the renin–angiotensin system, either an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin receptor blocker), at maximal or maximally tolerated doses.


Treatment Resistant Hypertension Epidemiology Segmentation in the 7MM

  • Total Treatment Resistant Hypertension Prevalent Cases
  • Treatment Resistant Hypertension Age-specific Cases
  • Treatment Resistant Hypertension Gender-specific Cases


Download the report to understand which factors are driving Treatment-resistant Hypertension epidemiology trends @ Treatment-resistant Hypertension Epidemiological Insights


Treatment-resistant Hypertension Treatment Market

The treatment for Resistant Hypertension is focused on the addition of fourth-line therapy where blood pressure is not controlled by treatment with three drugs, described by NICE as A + C + D: that is, an ACE inhibitor or an angiotensin II receptor blocker (A), a calcium channel antagonist (C), and a thiazide or thiazide-like diuretic (D). The most recommended drug therapy for Resistant Hypertension as a fourth-line agent is spironolactone in patients with potassium of 4.5 mmol/L, it is recommended that the existing diuretic (thiazide or thiazide-like) be doubled.


Treatment Resistant Hypertension Market Dynamics

The Treatment-resistant Hypertension market dynamics are anticipated to change with the launch of first-in-class drugs for resistant hypertension with novel MoA, such as aprocitentan, CIN-107, and others. Despite being the first-choice Resistant Hypertension medicine as an add-on therapy option for RHTN patients, there is an urgent unmet need for alternative therapeutic choices with a better side-effect profile, innovative MoA, simplicity of administration, etc which will drive the Treatment-resistant Hypertension market.


To know about more new drugs for Treatment-resistant Hypertension treatment visit @ Treatment-resistant Hypertension Medications


Scope of the Treatment-resistant Hypertension Market Report

  • Study Period: 2019-2032
  • Coverage: 7MM
  • Treatment-resistant Hypertension Companies: Idorsia Ltd, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences, and others
  • Treatment-resistant Hypertension Pipeline Therapies: Aprocitentan, Firibastat (QGC001), CIN-107, IONIS-AGT-LRx, and others
  • Treatment Resistant Hypertension Market Dynamics: Treatment Resistant Hypertension Market Drivers and Barriers
  • Treatment Resistant Hypertension Market Access and Reimbursement, Unmet Needs


Discover more about the future Treatment-resistant Hypertension market share of treatment therapies @ Treatment Resistant Hypertension Treatment Landscape


Table of Content

1. Key Insights

2. Treatment Resistant Hypertension Report Introduction

3. Treatment-resistant Hypertension (RHTN) Market Overview at a Glance

4. Executive Summary of Treatment-resistant Hypertension

5. Disease Background and Overview

6. Treatment Resistant Hypertension Epidemiology and Patient Population

7. Treatment Resistant Hypertension Patient Journey

8. Treatment Resistant Hypertension Emerging Therapies

9. Other Promising Therapies

10. Treatment-resistant Hypertension (RHTN): 7 Major Market Analysis

11. SWOT Analysis

12. Treatment Resistant Hypertension Unmet Needs

13. KOL Views

14. Appendix

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight


Get in touch with our Business executive @ Treatment Resistant Hypertension Market Drivers and Barriers


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States